What is Colgate-Palmolive Company's stock symbol?
Colgate-Palmolive Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "CL."
How often does Colgate-Palmolive Company pay dividends? What is the dividend yield for Colgate-Palmolive Company?
Colgate-Palmolive Company declared a quarterly dividend on Thursday, January 12th. Investors of record on Monday, January 23rd will be given a dividend of $0.39 per share on Wednesday, February 15th. This represents a $1.56 annualized dividend and a dividend yield of 2.13%. The ex-dividend date is Thursday, January 19th.
Where is Colgate-Palmolive Company's stock going? Where will Colgate-Palmolive Company's stock price be in 2017?
16 equities research analysts have issued 1 year price objectives for Colgate-Palmolive Company's shares. Their predictions range from $68.00 to $80.00. On average, they expect Colgate-Palmolive Company's stock price to reach $73.64 in the next twelve months.
When will Colgate-Palmolive Company announce their earnings?
Colgate-Palmolive Company is scheduled to release their next quarterly earnings announcement on Friday, April, 28th 2017.
What are analysts saying about Colgate-Palmolive Company stock?
Here are some recent quotes from research analysts about Colgate-Palmolive Company stock:
- B. Riley analysts commented, "Colgate (CL) reported 4Q16 EPS of $0.75 vs. $0.73, in line with consensus and $0.01 below our estimate. Op. profit of $1,038MM (+2% YoY) fell short of consensus of $1,071MM. Organic sales were +1.5% (+4.6% exp.), with organic volume -1%'this was only the second quarter since 2002 with an organic volume decline for CL. Volume was impacted by the India demonetization and a distributor issue in Africa/ Eurasia; organic volume was up in only one of the six segments. CL expects organic sales +4% in 2017, and cut EPS guidance from up double-digits to up low-single digits, due to FX and lower category growth rates. We are lowering our 2017E/2018E EPS by $0.20 each to $2.90/$3.20 and our PT from $78.00 to $74.00, based on 23x 2018E EPS of $3.20. While 3% EPS growth in 2017 looks achievable (even conservative), we are concerned by how much marketing investment, and competitive 'catching up,' is implied. If interest rates go higher in 2017, staples stocks may have a tough time outperforming, but we view Procter & Gamble (PG; Buy; $106.00 PT) as more attractive than CL, because PG's organic sales growth is driving higher toward 3%, while CL's has been decelerating. As the gap continues to narrow between CL's and PG's organic sales growth rates, we think investors will become increasingly attracted to PG. The two stocks' valuations are similar on EV-to-EBITDA." (1/29/2017)
- Berenberg Bank analysts commented, "Colgate has an enviable position in oral care..: Nearly half of Colgate's sales are in oral care, a category in which the growth outlook remains robust, and high consolidation/low innovation requirements facilitate profitable growth. Its second-largest category, pet nutrition, also has attractive characteristics; however, the rest of HPC is less appealing."'Although not enough to sustain its top-line growth premium: Colgate's growth premium has faded, disappearing in 2016 as market share gains eased and organic growth slowed to 4%. Before 2010, over a third of Colgate's growth came from outperformance whereas in aggregate its market share has not changed since 2010. While we expect organic growth to improve (to 5% in 2017E-19E), helped by a step-up in innovation, it will remain below history and at only a small premium to peers. High existing market shares, particularly in oral care, will inhibit further share gains." (1/25/2017)
According to Zacks Investment Research, "Shares of Colgate have underperformed the broader industry in the last six months due to the perils of currency headwinds, which has been hurting the company’s results to some extent. As the company derives 75% of its revenues from operations outside the U.S., it expects the macroeconomic headwinds and currency woes to linger and weigh on its top and bottom lines in 2016. Also, stiff competition remains a threat. Estimates have been going down lately ahead of the company’s fourth-quarter earnings release. However, Colgate anticipates delivering robust organic sales growth backed by new products across categories and geographical regions. The company's product innovation, globally recognized brands and presence in both developed and emerging economies enables it to capture growth opportunities and boost profitability. The company’s international brand recognition and innovative strategies underscore its inherent strength." (12/27/2016)
J P Morgan Chase & Co analysts commented, "Colgate delivered a penny of EPS upside in Q2, which was primarily driven by better than anticipated gross margins. Although there were pockets of weakness (i.e. China, Brazil, France, etc.), we believe the company’s business remains relatively healthy. We remain on the sidelines given hefty valuation." (7/29/2016)
Morgan Stanley analysts commented, "We rate CL EW, as we believe the stock’s valuation premium vs. peers appropriately reflects superior growth prospects. What’s Changed? What’s Changed? From: From: To: To: Colgate-Palmolive Co Colgate-Palmolive Co Price Target $72.00 $75.00 Solid Q1 EPS: Colgate Q1 EPS of $0.63 was in line with our on-consensus $0.63 estimate despite higher taxes hurting EPS by a penny. Results were generally in-line (which is good news in a tough Q1 EPS season for CPG peers so far), with -0.3% topline downside, but +0.4% gross profit and +1.4% operating profit upside vs consensus. +5.0% organic sales growth (est. 4.9% unrounded) was slightly above the +4.8% consensus estimate (5.3% MSe), and market expectations probably in the ~4.5% range. CL’s+5.0% organic sales result was much better than its large cap peer average (includes PG/KO/PEP) in the ~2.5% range. GM’s came in 40 bps above consensus, with CL hitting 60% GM’s for the first time in their history, while SG&A was 10 bp below consensus as a % of sales, driving 1.4% operating profit upside, likely due to ad spend which was -7% yoy, in line with the reported sales decline, and 60 bps below our forecast as a % of sales. Emerging markets organic sales were up a robust +7.5%, in line with the average trend over the prior few quarters." (4/29/2016)
Who owns Colgate-Palmolive Company stock?
Colgate-Palmolive Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (6.86%), FMR LLC (4.35%), Renaissance Technologies LLC (0.95%), Baillie Gifford & Co. (0.61%), Franklin Resources Inc. (0.51%) and Fiera Capital Corp (0.41%). Company insiders that own Colgate-Palmolive Company stock include Daniel B Marsili, Delano E Lewis, Delia H Thompson, Dennis J Hickey, Ellen M Hancock, Fabian T Garcia, Franck J Moison, Ian M Cook, Jennifer Daniels, John J Huston, John T Cahill, Justin Skala, Mukul Deoras, Noel R Wallace, Patricia Verduin, Richard J Kogan, Stephen I Sadove and Victoria L Dolan.
Who sold Colgate-Palmolive Company stock? Who is selling Colgate-Palmolive Company stock?
Colgate-Palmolive Company's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Baillie Gifford & Co., Bessemer Group Inc., Marshall Wace LLP, Artemis Investment Management LLP, Main Street Research LLC, Janus Capital Management LLC and Cipher Capital LP. Company insiders that have sold Colgate-Palmolive Company stock in the last year include Delia H Thompson, Dennis J Hickey, Ellen M Hancock, Franck J Moison, Ian M Cook, Jennifer Daniels, John J Huston, John T Cahill, Justin Skala, Mukul Deoras, Noel R Wallace, Patricia Verduin, Richard J Kogan, Stephen I Sadove and Victoria L Dolan.
Who bought Colgate-Palmolive Company stock? Who is buying Colgate-Palmolive Company stock?
Colgate-Palmolive Company's stock was bought by a variety of institutional investors in the last quarter, including DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., Renaissance Technologies LLC, Asset Management One Co. Ltd., Two Sigma Investments LP, Congress Asset Management Co. MA, AKO Capital LLP and Northcape Capital Pty Ltd.
How do I buy Colgate-Palmolive Company stock?
Shares of Colgate-Palmolive Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Colgate-Palmolive Company stock cost?
One share of Colgate-Palmolive Company stock can currently be purchased for approximately $73.18.